secwatch.observer — SEC 8-K summary
======================================

Issuer:     Telomir Pharmaceuticals, Inc. (TELO)
CIK:        0001971532
Form:       8-K
Filed at:   2025-05-15T23:59:59+00:00
Accession:  0001641172-25-010518
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Telomir identifies Telomir-Ag2, stabilized Silver(II) complex with broad-spectrum antibacterial activity
--------------------------------------------------------------------------------

- Telomir-Ag2 is a novel drug candidate from the proprietary Telomir-1 platform, stabilized Silver(II).
- Minimum Inhibitory Concentration (MIC) study shows broad-spectrum activity against Gram-positive and Gram-negative strains.
- Active against methicillin- and aminoglycoside-resistant Staphylococcus aureus (MARSA).
- Telomir-Ag2 exhibited greater antibacterial activity than the earlier Silver(I)-based Telomir-Ag1 formulation.
- Company plans formulation development and regulatory pathways targeting drug-resistant infections in burn wounds and post-surgical settings.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971532/000164117225010518/0001641172-25-010518-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971532/000164117225010518/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-010518

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer